Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > NexImmune Appoints Kenneth Carter, PhD, as President and CEO and Jonathan Schneck, MD, PhD as Chairman of Clinical and Scientific Advisory Board: Licenses Technology From The Johns Hopkins University

Abstract:
NexImmune, an early stage biopharmaceutical company, announced today the appointment of Kenneth Carter, PhD, as the company's President and Chief Executive Officer, and Professor Jonathan Schneck, MD, PhD, as Chairman of the company's Clinical and Scientific Advisory Board. At the same time, NexImmune announced that the company has licensed the Artificial IMmune (AIM™) nanotechnology for immuno-therapy, developed by Dr. Mathias Oelke and Dr. Schneck's laboratory from The Johns Hopkins University.

NexImmune Appoints Kenneth Carter, PhD, as President and CEO and Jonathan Schneck, MD, PhD as Chairman of Clinical and Scientific Advisory Board: Licenses Technology From The Johns Hopkins University

Gaithersburg, MD | Posted on January 4th, 2012

Prior to NexImmune, Dr. Carter was the President, CEO and a co-founder of Noble Life Sciences. Dr. Carter has also played a key leadership role in launching several other biotechnology companies including Avalon Pharmaceuticals, Inc. where he served as CEO for 10 years until 2009 when Avalon merged with Clinical Data, Inc. During his tenure at Avalon, the company developed a unique biomarker-based drug discovery and development engine; completed an IPO and listing on the NASDAQ market; established drug discovery programs in colon, breast, pancreatic and hematological cancers; and established partnerships with Merck, Novartis, Sanofi-Aventis, and AstraZeneca/MedImmune. Prior to Avalon, Dr. Carter directed the gene mapping initiative at Human Genome Sciences, Inc. where he played a lead role in the discovery, cloning, and chromosomal mapping of dozens of novel human genes. Dr. Carter serves on the Advisory Council for the Center for Biotechnology Education at The Johns Hopkins University where he also holds an adjunct faculty appointment.

"The AIM technology provides an exciting leap in immuno-therapy for a variety of cancer and other diseases whereby artificial cells direct specific immune responses against a specific disease. I am very pleased to lead the team that will commercialize this exciting new technology. Our first development target will be a therapeutic to treat melanoma," said Dr. Carter.

Dr. Schneck is Professor of Pathology, Medicine and Oncology at Johns Hopkins School of Medicine. He is well known for several key scientific contributions to the field including extensive work in the artificial manipulation of immune system components in order to maximize T cell responses. To facilitate the study of both normal and aberrant immune responses, he and his laboratory have developed a variety of innovative nano-molecular tools including the DimerX technology, for analysis of antigen-specific T cells, marketed by BD Biosciences, and artificial Antigen Presenting Cell (aAPC), the foundation of the AIM technology. The quality and potential of Dr. Schneck's scientific work has been well recognized with excellent support from granting agencies including Dr. Schneck leading a team of investigators that were awarded a $12 million grant in 2009, the largest basic science immunology grant in the history of Johns Hopkins University. Dr. Schneck has more than 200 scientific publications and is an inventor on several dozen submitted and granted patents.

"It is terrific to work with Ken and his team on the commercial transformation of the AIM technology to a product development platform. If the products to be developed by NexImmune are successful in human clinical trials, I believe the AIM technology has the potential to provide a major step forward for immuno-therapy for a variety of diseases," said Dr. Schneck.

####

About NexImmune, Inc.
NexImmune is an early stage biopharmaceutical company developing novel immuno-therapeutics based on the proprietary Artificial IMmune (AIM™) nanotechnology platform. Central to the AIM™ technology are artificial Antigen Presenting Cells (aAPCs) that can be engineered to orchestrate a highly specific immune attack directed toward any foreign substance or cell type in the body. In pre-clinical studies, aAPCs have been shown to have potential utility as vaccines and therapeutic agents and can also be used for the development of diagnostic products. NexImmune is using the AIM technology platform to develop a pipeline of products to treat cancer. The company's first therapeutic will be targeted at the treatment of advanced stage melanoma.

For more information, please click here

Contacts:
NexImmune, Inc.
22 Firstfield Road
Suite 280
Gaithersburg, MD 20878
phone: 301-685-1688
website www.neximmune.com

Media Contact Information:
Faye Coggins
301-685-1688 ext.104

Copyright © Marketwire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Multi-million pound project to use nanotechnology to improve safety September 4th, 2015

Magnetic wormhole connecting 2 regions of space created for the first time: The device could have applications in medicine, opening up ways to make MRIs more comfortable for patients September 4th, 2015

Tongfang Global and QD Vision Partner to Bring Wide Color Gamut to Global Television Lines: Color IQTM quantum dots help boost company’s focus on superior color reproduction September 3rd, 2015

QEOS and GLOBALFOUNDRIES to Offer Industry’s First CMOS Platform for MillimeterWave Markets: GLOBALSOLUTIONSSM Partnership will enable next-generation wireless technologies for applications in IoT, 5G and automotive September 3rd, 2015

Nanomedicine

Magnetic wormhole connecting 2 regions of space created for the first time: The device could have applications in medicine, opening up ways to make MRIs more comfortable for patients September 4th, 2015

Making nanowires from protein and DNA September 3rd, 2015

Reversible Writing with Light: Self-assembling nanoparticles take their cues from their surroundings September 3rd, 2015

Silk bio-ink could help advance tissue engineering with 3-D printers September 2nd, 2015

Announcements

Multi-million pound project to use nanotechnology to improve safety September 4th, 2015

Magnetic wormhole connecting 2 regions of space created for the first time: The device could have applications in medicine, opening up ways to make MRIs more comfortable for patients September 4th, 2015

Making nanowires from protein and DNA September 3rd, 2015

Making fuel from light: Argonne research sheds light on photosynthesis and creation of solar fuel September 3rd, 2015

Patents/IP/Tech Transfer/Licensing

An engineered surface unsticks sticky water droplets August 31st, 2015

Developing Component Scale Composites Using Nanocarbons August 26th, 2015

Industrial Nanotech, Inc. Provides Update On Hospital Project, PCAOB Audit, and New Heat Shield™ Line August 24th, 2015

Revolutionary MIT-Developed Nanotechnology Company Showcases at CAMX in Dallas August 20th, 2015

Appointments/Promotions/New hires/Resignations/Deaths

National Space Society Welcomes Janet Ivey As New NSS Governor: Janet Ivey of Janet's Planet is NOW IN ORBIT as a member of the Board of Governors of the National Space Society August 27th, 2015

National Space Society Welcomes Geoff Notkin As New NSS Governor August 26th, 2015

Nanostart AG: First-half figures 2015 published and new supervisory board elected : Publication of first-half figures 2015 - Shareholders' meeting elected new supervisory board August 22nd, 2015

Markus Lusser is New President of Leica Microsystems August 11th, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic